Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L.
Karen L ReckampHuamao Mark LinHolly L CranmerYanyu WuPingkuan ZhangStephen KayLaura J WaltonJunwu ShenSanjay PopatD Ross CamidgePublished in: Current medical research and opinion (2022)
+ NSCLC previously untreated with an ALK inhibitor.